5-[3,4-Dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-[3,4-Dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
• 化学式: C₁₂H₂₂O₁₀
• 分子量: 326.3
• InChiKey: DSYGIMVFFQCOQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  169
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• [EN] MODULAR SYNTHESIS OF AMPHIPHILIC JANUS GLYCODENDRIMERS AND THEIR SELF-ASSEMBLY INTO GLYCODENDRIMERSOMES<br/>[FR] SYNTHÈSE MODULAIRE DE GLYCODENDRIMÈRES AMPHIPHILES DE TYPE JANUS ET LEUR AUTOASSEMBLAGE EN GLYCODENDRIMÈRESOMES
  申请人：PERCEC VIRGIL

  公开号：WO2014190024A1

  公开（公告）日：2014-11-27

  The invention concerns compounds of the formula (I) wherein: Y1 and Y2 are independently a monosaccharide or disaccharide; X1 and X2 are independently -(R9-O)m-, -(R10)P-, -O-(R11-O)q-, -R16-O-R17-O- or a covalent bond; Q1 and Q2 are independently a nitrogen-containing heterocycle moiety; Z1 and Z2 are independently -(O-R7)-, -(O-C(=O)-R8)a-, -O-C(=O)-R12-C(=0)-R13-, -O- C(=O)-R14-C(=O)-R15 or a covalent bond; R7-R17 are each independently C1-C6 alkyl; R1-R6 are each independently a linear or branched alkly group; b, c, d, e, f, and g are 0 or 1, provided b + c + d equals at least 2 and e + f + g equals at least 2; and a, m, p, and q are each an integer from 1-6.

  该发明涉及式(I)的化合物，其中：Y1和Y2分别是单糖或二糖；X1和X2分别是-(R9-O)m-，-(R10)P-，-O-(R11-O)q-，-R16-O-R17-O-或共价键；Q1和Q2分别是含氮杂环基；Z1和Z2分别是-(O-R7)-，-(O-C(=O)-R8)a-，-O-C(=O)-R12-C(=0)-R13-，-O- C(=O)-R14-C(=O)-R15或共价键；R7-R17各自独立地是C1-C6烷基；R1-R6各自独立地是线性或支链烷基；b、c、d、e、f和g为0或1，但要求b + c + d至少等于2，e + f + g至少等于2；a、m、p和q各自是1-6的整数。
• [EN] MODIFIED iRNA AGENTS<br/>[FR] AGENTS À BASE D'ARNI MODIFIÉS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2012037254A1

  公开（公告）日：2012-03-22

  The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions.